CNS Pharmaceuticals, Inc. (CNSP)
Nasdaq: CNSP · Pharmaceutical Preparations · Houston, TX · filing with the SEC since 2018
Who owns CNS Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
2
Ikarian Capital, LLC holds 9.9% of Common Stock, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
11
report now, of 13 people on the record since 2019. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Ikarian Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 5.7% in Apr 17, 2026
Stonepine Capital Management, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock · 7.9% in Feb 13, 2026
Armistice Capital, LLC
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock · reported falling below 5%, from 9.99% in Aug 14, 2025
What CNSP reports owning in othersstakes of 5% or more, and other ties
CNS Pharmaceuticals, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
2purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 15 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Fisher Michal | director | 0 | $0 | 0 | 1 | $0 |
| Charles Faith L. | director | 0 | $0 | 0 | 1 | $0 |